Cargando…
Rapid diagnostic tests for infectious diseases in the emergency department
BACKGROUND: Rapid diagnostic tests (RDTs) for infectious diseases, with a turnaround time of less than 2 hours, are promising tools that could improve patient care, antimicrobial stewardship and infection prevention in the emergency department (ED) setting. Numerous RDTs have been developed, althoug...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129254/ https://www.ncbi.nlm.nih.gov/pubmed/32120036 http://dx.doi.org/10.1016/j.cmi.2020.02.024 |
_version_ | 1783516744685453312 |
---|---|
author | Bouzid, D. Zanella, M.-C. Kerneis, S. Visseaux, B. May, L. Schrenzel, J. Cattoir, V. |
author_facet | Bouzid, D. Zanella, M.-C. Kerneis, S. Visseaux, B. May, L. Schrenzel, J. Cattoir, V. |
author_sort | Bouzid, D. |
collection | PubMed |
description | BACKGROUND: Rapid diagnostic tests (RDTs) for infectious diseases, with a turnaround time of less than 2 hours, are promising tools that could improve patient care, antimicrobial stewardship and infection prevention in the emergency department (ED) setting. Numerous RDTs have been developed, although not necessarily for the ED environment. Their successful implementation in the ED relies on their performance and impact on patient management. OBJECTIVES: The aim of this narrative review was to provide an overview of currently available RDTs for infectious diseases in the ED. SOURCES: PubMed was searched through August 2019 for available studies on RDTs for infectious diseases. Inclusion criteria included: commercial tests approved by the US Food and Drug Administration (FDA) or Conformité Européenne (CE) in vitro diagnostic devices with data on clinical samples, ability to run on fully automated systems and result delivery within 2 hours. CONTENT: A nonexhaustive list of representative commercially available FDA- or CE-approved assays was categorized by clinical syndrome: pharyngitis and upper respiratory tract infection, lower respiratory tract infection, gastrointestinal infection, meningitis and encephalitis, fever in returning travellers and sexually transmitted infection, including HIV. The performance of tests was described on the basis of clinical validation studies. Further, their impact on clinical outcomes and anti-infective use was discussed with a focus on ED-based studies. IMPLICATIONS: Clinicians should be familiar with the distinctive features of each RDT and individual performance characteristics for each target. Their integration into ED work flow should be preplanned considering local constraints of given settings. Additional clinical studies are needed to further evaluate their clinical effectiveness and cost-effectiveness. |
format | Online Article Text |
id | pubmed-7129254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71292542020-04-08 Rapid diagnostic tests for infectious diseases in the emergency department Bouzid, D. Zanella, M.-C. Kerneis, S. Visseaux, B. May, L. Schrenzel, J. Cattoir, V. Clin Microbiol Infect Narrative Review BACKGROUND: Rapid diagnostic tests (RDTs) for infectious diseases, with a turnaround time of less than 2 hours, are promising tools that could improve patient care, antimicrobial stewardship and infection prevention in the emergency department (ED) setting. Numerous RDTs have been developed, although not necessarily for the ED environment. Their successful implementation in the ED relies on their performance and impact on patient management. OBJECTIVES: The aim of this narrative review was to provide an overview of currently available RDTs for infectious diseases in the ED. SOURCES: PubMed was searched through August 2019 for available studies on RDTs for infectious diseases. Inclusion criteria included: commercial tests approved by the US Food and Drug Administration (FDA) or Conformité Européenne (CE) in vitro diagnostic devices with data on clinical samples, ability to run on fully automated systems and result delivery within 2 hours. CONTENT: A nonexhaustive list of representative commercially available FDA- or CE-approved assays was categorized by clinical syndrome: pharyngitis and upper respiratory tract infection, lower respiratory tract infection, gastrointestinal infection, meningitis and encephalitis, fever in returning travellers and sexually transmitted infection, including HIV. The performance of tests was described on the basis of clinical validation studies. Further, their impact on clinical outcomes and anti-infective use was discussed with a focus on ED-based studies. IMPLICATIONS: Clinicians should be familiar with the distinctive features of each RDT and individual performance characteristics for each target. Their integration into ED work flow should be preplanned considering local constraints of given settings. Additional clinical studies are needed to further evaluate their clinical effectiveness and cost-effectiveness. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-02 2020-02-29 /pmc/articles/PMC7129254/ /pubmed/32120036 http://dx.doi.org/10.1016/j.cmi.2020.02.024 Text en © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Narrative Review Bouzid, D. Zanella, M.-C. Kerneis, S. Visseaux, B. May, L. Schrenzel, J. Cattoir, V. Rapid diagnostic tests for infectious diseases in the emergency department |
title | Rapid diagnostic tests for infectious diseases in the emergency department |
title_full | Rapid diagnostic tests for infectious diseases in the emergency department |
title_fullStr | Rapid diagnostic tests for infectious diseases in the emergency department |
title_full_unstemmed | Rapid diagnostic tests for infectious diseases in the emergency department |
title_short | Rapid diagnostic tests for infectious diseases in the emergency department |
title_sort | rapid diagnostic tests for infectious diseases in the emergency department |
topic | Narrative Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129254/ https://www.ncbi.nlm.nih.gov/pubmed/32120036 http://dx.doi.org/10.1016/j.cmi.2020.02.024 |
work_keys_str_mv | AT bouzidd rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT zanellamc rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT kerneiss rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT visseauxb rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT mayl rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT schrenzelj rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment AT cattoirv rapiddiagnostictestsforinfectiousdiseasesintheemergencydepartment |